Ricky Sun is a partner at Bain Capital Life Sciences, investing and building companies that drive medical innovation. Prior to joining Bain Capital, he was a director of corporate development and strategy at Biogen. Before Biogen, Sun served as a vice president at BlackRock, as a member of the Fundamental Equity division of BlackRock’s Alpha Strategies Group, and senior analyst for BlackRock’s Fundamental Large Cap Growth equity team, covering the health-care sector. Ricky began his career as a senior scientist at Ironwood Pharmaceutical, where he was involved in the discovery and development of the drug Linzess for irritable bowel syndrome. He received a Ph.D. degree in chemistry and chemical biology from Harvard University and was an NIH postdoctoral fellow in biological chemistry and molecular pharmacology at Harvard Medical School. He also received an M.B.A. from New York University Stern School of Business, where he was a Mildred Elperin Scholar. He graduated summa cum laude from Berea College with a B.A. in chemistry. He is currently a member of the board of directors of Adarx, Avistone, Emalex, Savara, and Tenacia. Previously, he was a board member of Arcutis, Annexon, and served as board observer of Pharvaris and Replimune. He is also a member of the Boston Museum of Science Advisors. He and his wife, Cathy He, are the parents of two children, including one Winsor student.